NanoSurface Biomedical Awarded $1.9M in Funding from NIH
03/03/20, 5:06 PM
Location
seattleMoney raised
$1 million
Round Type
seed
NanoSurface Biomedical received $1.9 million in new funding in 2019 from the National Institutes of Health (NIH) to support accelerated development of NanoSurface’s innovative human induced pluripotent stem cell (iPSC)-based platforms for drug discovery and safety screening. This funding announcement brings the total non-dilutive Small Business Innovative Research (SBIR) funding NanoSurface has received from the NIH to $3.1 million. Under the terms of the funding awards, NanoSurface will receive an additional $1.5 million upon successful completion of scientific milestones.
Company Info
Location
seattle, washington, united states
Additional Info
NanoSurface Biomedical is a biotechnology company based in Seattle, WA that develops stem cell-based assay technologies to accelerate drug development. NanoSurface’s structurally matured cardiac tissue models, assay instruments, and discovery services leverage human stem cell technology to help pharmaceutical companies predictively assess the safety and efficacy of candidate drugs early during preclinical development. NanoSurface’s mission is to help bring life-saving medicines to market in less time and at lower cost. To learn more, visit www.nanosurfacebio.com.